BHVN vs TNXP
BHVN: Biohaven is a clinical-stage biopharmaceutical company developing innovative therapies for immunology, neurological disorders, and metabolic diseases using proprietary protein degradation and ion channel platforms. TNXP: A fully-integrated biopharmaceutical company commercializing TONMYA (cyclobenzaprine sublingual tablets) for fibromyalgia while advancing a pipeline of CNS, immunology, and infectious disease therapies.
Side-by-side fundamentals
| Metric | BHVN | TNXP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $14.75 | $10.59 | |
| Market cap as of 2026-07-23 | $2.3B | $184M | |
| Net margin as of 2026-07-23 | n/a | -839.5% | |
| Gross margin as of 2026-07-23 | n/a | +58.6% | |
| Operating margin as of 2026-07-23 | n/a | -861.2% | |
| ROE as of 2026-07-23 | -450.0% | -67.7% | TNXP higher |
| ROA as of 2026-07-23 | -138.0% | -60.5% | TNXP higher |
| Debt / equity as of 2026-07-23 | 1.87 | 0.00 | TNXP lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +74.8% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +29.9% | |
| Beta as of 2026-07-23 | 2.98 | 1.71 | |
| 1-year return as of 2026-07-22 close | +12.3% | -76.3% | BHVN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.